



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2020 P 3131-1
Program	Step Therapy
Medication	Zomig (zolmitriptan) nasal spray
P&T Approval Date	1/2020
Effective Date	7/1/2020; Oxford only: 7/1/2020

1. Background:

Zomig (zolmitriptan) nasal spray is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Zomig nasal spray is not intended for the prophylactic therapy of migraine attacks or for the treatment of cluster headache.

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try generic triptans before providing coverage for Zomig nasal spray.

2. Coverage Criteria^a:

A. Zomig (zolmitriptan) nasal spray will be approved based on the following criteria:

1. History of failure, contraindication, or intolerance to two of the following oral triptans:
 - a. almotriptan (Axert)
 - b. eletriptan (Relpax)
 - c. frovatriptan (Frova)
 - d. naratriptan (Amerge)
 - e. rizatriptan (Maxalt/Maxalt MLT)
 - f. sumatriptan (Imitrex)
 - g. zolmitriptan (Zomig)

-AND-

2. History of failure, contraindication, or intolerance to sumatriptan nasal spray (generic Imitrex nasal spray)

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.



3. Additional Clinical Programs:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

4. References:

1. Zomig [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; May 2019.

Program	Step Therapy – Zomig nasal spray
Change Control	
1/2020	New program.